Who
Jason Lettmann
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, ALX Oncology Holdings; Director and 10% owner, Ra Pharmaceuticals.
In numbers
- Trades disclosed
- 96
- Buys
- 5
- Sells
- 9
- Bought
- $12.9M
- Sold
- $13.7M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 31 Oct 2016
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $4,3042,230 at $1.93 | filing |
| 17 Aug 2026filed 18 Aug 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $4,3042,230 at $1.93 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $27K12,311 at $2.17 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $27K12,311 at $2.17 | filing |
| 17 Feb 2026filed 19 Feb 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Code F | $4,9962,201 at $2.27 | filing |
| 17 Feb 2026filed 19 Feb 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Code F | $4,9962,201 at $2.27 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —912,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —912,000 at $0.00 | filing |
| 14 Oct 2025filed 16 Oct 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —597,500 at $0.00 | filing |
| 17 Sep 2025filed 18 Sep 2025 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $77K71,163 at $1.08 | filing |
| 16 Sep 2025filed 18 Sep 2025 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $23K21,070 at $1.07 | filing |
| 15 Aug 2025filed 19 Aug 2025 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $1,5242,382 at $0.64 | filing |
| 11 Apr 2025filed 15 Apr 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Sold | $2,4832,159 at $1.15 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —478,000 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 14 Aug 2024filed 16 Aug 2024 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Code F | $5,6532,191 at $2.58 | filing |
| 14 Mar 2024filed 18 Mar 2024 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $50K4,400 at $11.31 | filing |
| 14 Feb 2024filed 16 Feb 2024 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.